Health Trials

Clinical trials

3

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

A Phase 2 Study on the Safety and Efficacy of the Anti-BAFF-R Monoclonal Antibody, ESG206, in Patients With Primary Sjogren Syndrome

This is a multicenter, randomized, double-blind, placebo-controlled Phase II study designed to evaluate the efficacy and safety of ESG206 in participants with primary Sjögren's syndrome.

Participants needed: 40
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Shanghai Escugen Biotechnology Co., LtdUpdated: Feb 3, 2026Locations: 21
Eligibility criteria

Adults (≥18 years of age) with a confirmed diagnosis of primary Sjögren's syndro... [+2]

Secondary Sjögren's syndrome or other clinically significant autoimmune or infla... [+3]

Read more
Status: Recruiting

Study of ESG406 in Adults With Solid Tumors

This study is an open-label, dose-escalation and cohort expansion Phase I study, aiming to evaluate the safety, tolerability, PK characteristics and preliminary efficacy of ESG406, and determine the MTD, RP2D and administration regimens of ESG406. The study includes the dose escalation study in Phase Ia and the cohort expansion study in Phase Ib.

Participants needed: 556
Trial details
Phase: Phase 1Age: 18-80Biological sex: AllType: InterventionalSponsor: Shanghai Escugen Biotechnology Co., LtdUpdated: Sep 12, 2025Locations: 3
Eligibility criteria

Males and females aged 18 to 80 years. [+6]

Use of any cancer therapy (chemotherapy or other systemic anti-cancer therapies,... [+13]

Read more
Status: Recruiting

A Phase 1/2 Study of ESG206 in Patients With Primary Immune Thrombocytopenia

This is a multicenter, open-label Phase1/2 study aimed at evaluating the safety, tolerability, pharmacokinetic (PK) profile, pharmacodynamics (PD), immunogenicity, and preliminary efficacy of ESG206. The study will be conducted in patients with primary immune thrombocytopenia.

Participants needed: 84
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Shanghai Escugen Biotechnology Co., LtdUpdated: May 16, 2025Locations: 1
Eligibility criteria

1. Willing and able to provide written informed consent for this trial. [+7]

1. Diagnosed with secondary immune thrombocytopenia, or there is evidence that t... [+20]

Read more